PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

被引：218

作者：

Carpinelli, Patrizia ^{[1
]}

Ceruti, Roberta ^{[1
]}

Giorgini, Maria Laura ^{[1
]}

Cappella, Paolo ^{[1
]}

Gianellini, Laura ^{[1
]}

Croci, Valter ^{[1
]}

Degrassi, Anna ^{[1
]}

Texido, Gernma ^{[1
]}

Rocchetti, Maurizio ^{[1
]}

Vianello, Paola ^{[1
]}

Rusconi, Luisa ^{[1
]}

Storici, Paola ^{[1
]}

Zugnoni, Paola ^{[1
]}

Arrigoni, Claudio ^{[1
]}

Soncini, Chiara ^{[1
]}

Alli, Cristina ^{[1
]}

Patton, Veronica ^{[1
]}

Marsiglio, Aurelio ^{[1
]}

Ballinari, Dario ^{[1
]}

Pesenti, Enrico ^{[1
]}

Fancelli, Daniele ^{[1
]}

Moll, Jurgen ^{[1
]}

机构：

[1] Nerviano Med Sci SRI Oncol, I-20014 Milan, Italy

来源：

MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期

关键词：

D O I：

10.1158/1535-7163.MCT-07-0444

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PHA-739358 is a small-molecule 3-aminopyrazole derivative with strong activity against Aurora kinases and cross-reactivities with some receptor tyrosine kinases relevant for cancer. PHA-739358 inhibits all Aurora kinase family members and shows a dominant Aurora B kinase inhibition related cellular phenotype and mechanism of action in cells in vitro and in vivo. p53 status-dependent endoreduplication is observed upon treatment of cells with PHA-739358, and phosphorylation of histone H3 in Ser(10) is inhibited. The compound has significant antitumor activity in different xenografts and spontaneous and transgenic animal tumor models and shows a favorable pharmacokinetic and safety profile. In vivo target modulation is observed as assessed by the inhibition of the phosphorylation of histone H3, which has been validated preclinically as a candidate biomarker for the clinical phase. Pharmacokinetics/pharmacodynamics modeling was used to define drug potency and to support the prediction of active clinical doses and schedules. We conclude that PHA-739358, which is currently tested in clinical trials, has great therapeutic potential in anticancer therapy in a wide range of cancers.

引用

页码：3158 / 3168

页数：11

共 49 条

[1] Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1
Andreassen, PR
Lohez, OD
Lacroix, FB
Margolis, RL
[J]. MOLECULAR BIOLOGY OF THE CELL, 2001, 12 (05) : 1315 - 1328
[2] Sunitinib maleate
Atkins, M
Jones, CA
Kirkpatrick, P
[J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (04) : 279 - 280
[3] Structural basis of Aurora-A activation by TPX2 at the mitotic spindle
Bayliss, R
Sardon, T
Vernos, I
Conti, E
[J]. MOLECULAR CELL, 2003, 12 (04) : 851 - 862
[4] A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers
Bischoff, JR
Anderson, L
Zhu, YF
Mossie, K
Ng, L
Souza, B
Schryver, B
Flanagan, P
Clairvoyant, F
Ginther, C
Chan, CSM
Novotny, M
Slamon, DJ
Plowman, GD
[J]. EMBO JOURNAL, 1998, 17 (11) : 3052 - 3065
[5] Bongarzone I, 1998, CLIN CANCER RES, V4, P223
[6] POINT MUTATION OF THE RET PROTOONCOGENE IN THE TT HUMAN MEDULLARY-THYROID CARCINOMA CELL-LINE
CARLOMAGNO, F
SALVATORE, D
SANTORO, M
DEFRANCISCIS, V
QUADRO, L
PANARIELLO, L
COLANTUONI, V
FUSCO, A
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 207 (03) : 1022 - 1028
[7] The cellular geography of aurora kinases
Carmena, M
Earnshaw, WC
[J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (11) : 842 - 854
[8] Aurora kinases: New targets for cancer therapy
Carvajal, Richard D.
Tse, Archie
Schwartz, Gary K.
[J]. CLINICAL CANCER RESEARCH, 2006, 12 (23) : 6869 - 6875
[9] Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies
Clarkson, B
Strife, A
Wisniewski, D
Lambek, CL
Liu, C
[J]. LEUKEMIA, 2003, 17 (07) : 1211 - 1262
[10] Mitotic phosphorylation of histone H3: Spatio-temporal regulation by mammalian aurora kinases
Crosio, C
Fimia, GM
Loury, R
Kimura, M
Okano, Y
Zhou, HY
Sen, S
Allis, CD
Sassone-Corsi, P
[J]. MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (03) : 874 - 885

← 1 2 3 4 5 →